Search | IOVS | ARVO Journals

View

Showing 1 – 12 of 12

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Articles April 2021

Predictive Association of Pre-Operative Defect Areas in the Outer Retinal Layers With Visual Acuity in Macular Hole Surgery

PDF

Carmen Baumann; Danilo Iannetta; Ziyaad Sultan; Ian A. Pearce; Chris P. Lohmann; Yalin Zheng; Stephen B. Kaye
TAGS: embryonic lethal mutation, repair of hole of macula lutea, visual acuity, postoperative care
Trans. Vis. Sci. Tech.. 2021; 10(4):7. doi: https://doi.org/10.1167/tvst.10.4.7

ARVO Annual Meeting Abstract July 2019

Acceptability of OCT Angiography: A multicentre OCT Angiography NEtwork (OCTANE) study.

Faruque Ghanchi; Corinne Fulcher; Sobha Sivaprasad; Konstantinos Balaskas; Richard Peter Gale; Gabriella De Salvo; James S Talks; Andrew Lotery; Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3477. doi:

ARVO Annual Meeting Abstract July 2019

Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy

Zhihang Cheng; Salma Babiker; Pauline Lenfestey; Nick Beare; Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5002. doi:

ARVO Annual Meeting Abstract June 2017

Clinical characteristics and treatment outcomes in Central Serous Chorioretinopathy with secondary choroidal neovascularisation.

Danilo Iannetta; Savitha Madhusudhan; Nicholas V Beare; Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2315. doi:

ARVO Annual Meeting Abstract September 2016

Real-world outcomes of ranibizumab treatment in patients with retinal vein occlusion: the LUMINOUS™ study

Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5155. doi:

ARVO Annual Meeting Abstract September 2016

Grading OCT characteristics did not clearly predict treatment outcomes in the RELIGHT study participants

Tunde Peto; Usha Chakravarthy; Susanne Lupton; Kara Gibson; James Warburton; Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2084. doi:

ARVO Annual Meeting Abstract June 2015

One-year outcomes of ranibizumab treatment in a cohort of patients with retinal vein occlusion: an interim analysis from the real-world LUMINOUS study

Ian A Pearce; Ayan Das Gupta; Sue Lacey; LUMINOUS

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3743. doi:

ARVO Annual Meeting Abstract April 2014

Ranibizumab treatment of diabetic macular edema with bimonthly monitoring: 18-month outcomes of the Phase IIIb multicenter RELIGHT study

Ian A Pearce; RELIGHT study group

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1701. doi:

ARVO Annual Meeting Abstract April 2014

Use of dexamethasone implant for refractory CME secondary to uveitis

Nikolaos Krassas; Natasha Spiteri; Nicholas Beare; Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5308. doi:

ARVO Annual Meeting Abstract April 2014

Efficacy and safety of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to central retinal vein occlusion: Design and baseline characteristics of the CRYSTAL study

Francesco Boscia; Heinrich Gerding; Ian A Pearce; Siegfried Priglinger; Ramin Tadayoni; Jackie Han; George Lambrou; William John Stubbings; Jordi M Mones

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):606. doi:

ARVO Annual Meeting Abstract April 2014

Ranibizumab ±adjunctive laser vs laser in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO): Design and baseline characteristics of the BRIGHTER study

Heinrich Gerding; Francesco Boscia; Jordi M Mones; Siegfried Priglinger; Ramin Tadayoni; Jackie Han; George Lambrou; William John Stubbings; Ian A Pearce

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):607. doi:

ARVO Annual Meeting Abstract March 2012

Preliminary Results Of Treatment With Intravitreal Methotrexate In Patients With Macula Oedema Secondary To Uveitis

Manon E. Owen; George Morphis; Nicholas A. Beare; Ian A. Pearce

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1179. doi:

Advertisement